Results 251 to 260 of about 30,075 (311)

Specialized Pro-Resolving Lipid Mediators in Pulmonary Diseases: Molecular and Therapeutic Implications. [PDF]

Molecules
Ortega Á, Duran P, Garrido B, Manzano A, Navarro C, Silva A, Rojas M, De Sanctis JB, Radzioch D, Rivera-Porras D, Paredes CS, Bermúdez V.   +11 more
europepmc   +1 more source

Climate Justice Strategies Implemented by Public Health Nurses and Their Community Partners

Journal of Advanced Nursing, EarlyView.
ABSTRACT Aim To describe nurses' and community‐based organization representatives' collaborative strategies for advancing climate justice with communities. Design This study used a descriptive, qualitative research design. Methods Data were gathered from August 2022 to February 2023 with nurses (n = 8) and their community partners (n = 5) in the United
Jessica LeClair, Alex Dudek, Susan Zahner   +2 more
wiley   +1 more source

What is the true target population for biologics in real-life COPD or asthma-COPD overlap patients? [PDF]

BMJ Open Respir Res
Zysman M, Herman F, Grassion L, Taillé C, Gonzalez-Bermejo J, Guecamburu M, Roche N, Pavot A, Girodet PO, Bourdin A, Molinari N, Berger P, COBRA Study Group.   +12 more
europepmc   +1 more source

Treatment of juvenile bullous pemphigoid with lebrikizumab

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Marcel Wittenberg, Farzan Solimani, Amrei Dilling, Rawan Snobar, Kamran Ghoreschi, Marisa Klemp, Kerstin Kusch   +6 more
wiley   +1 more source

Effect of SGLT‐2 inhibitors on COPD exacerbations in individuals with type 2 diabetes: A meta‐analysis and Bayesian sensitivity analysis

Journal of Diabetes Investigation, EarlyView.
This systematic review and meta‐analysis evaluates the impact of SGLT‐2 inhibitors on COPD exacerbations in patients with Type 2 diabetes mellitus (T2DM). Our findings demonstrate that SGLT‐2 inhibitors significantly reduce the frequency of COPD exacerbations by 35% compared to other antidiabetic agents, offering dual benefits in glycemic control and ...
Muhammed Shabil, Jayaraj Patil, Prakasini Satapathy, Abhay M Gaidhane, Kattela Chennakesavulu, Nasir Vadia, Soumya V Menon, Rajashree Panigrahi, Ganesh Bushi, Mahendra Singh, Sanjit Sah, Awakash Turkar, Khang Wen Goh, S. Govinda Rao, Edward Mawejje   +14 more
wiley   +1 more source

Angiogenesis Factors as Emerging Circulating Biomarkers in Asthma. [PDF]

Allergy Asthma Immunol Res
Lee PH, An MH, Jang AS.
europepmc   +1 more source

European Guideline (EuroGuiDerm) on atopic eczema: Living update

Journal of the European Academy of Dermatology and Venereology, EarlyView.
The updated guideline includes a new evidence‐based recommendation for the IL‐13 inhibitor lebrikizumab. In addition, the Janus kinase inhibitors baricitinib and abrocitinib, which were initially only approved for adult patients, are now also recommended for children from the age of 2 and adolescents from the age of 12, respectively.
A. Wollenberg, M. Kinberger, B. Arents, N. Aszodi, S. Barbarot, T. Bieber, H. A. Brough, P. Calzavara‐Pinton, S. Christen‐Zaech, M. Deleuran, M. Dittmann, N. Fosse, K. Gáspár, L. A. A. Gerbens, U. Gieler, G. Girolomoni, S. Gregoriou, S. Holland, C. G. Mortz, A. Nast, U. Nygaard, E. M. Rehbinder, J. Ring, M. Rossi, E. Serra‐Baldrich, D. Simon, Z. Z. Szalai, J. C. Szepietowski, A. Torrelo, T. Werfel, R. N. Werner, C. Flohr   +31 more
wiley   +1 more source

The molecular circadian clock of eosinophils: a potential therapeutic target for asthma. [PDF]

Am J Physiol Cell Physiol
Teppan J, Bärnthaler T, Farzi A, Durrington H, Gioan-Tavernier G, Platt H, Wolf P, Heinemann A, Böhm E.   +8 more
europepmc   +1 more source

Infection risk in atopic dermatitis patients treated with biologics and JAK inhibitors: BioDay results

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This cohort study of 1793 atopic dermatitis patients (aged ≥ 12) found higher infection rates with Janus kinase inhibitor treatment compared to biologic treatment, particularly for herpes infections, with a history of viral or fungal skin infection as a risk factor associated with infection.
Lian F. van der Gang, Keneshka Atash, Nicolaas P. A. Zuithoff, Inge Haeck, Celeste M. Boesjes, Octavian I. Bacoş‐Cosma, Laura Loman, Marijke Kamsteeg, Simone Stadhouders‐Keet, Albert J. Oosting, Anneke M. T. van Lynden‐van Nes, Klaziena Politiek, Antoni Gostynksi, Lisette Berntsen‐Zandbergen, Wianda A. Christoffers, Annebeth Flinterman, Wouter R. H. Touwslager, Berit Velstra, Shiarra M. Stewart, Francine C. van Erp, Marlies de Graaf, Marie‐Louise A. Schuttelaar, Marjolein S. de Bruin‐Weller   +22 more
wiley   +1 more source

The clinical and pathological histology efficacy of biological therapy for severe asthma with a phenotype of type 2 inflammation - systematic review. [PDF]

Front Immunol
Ma J, Ma Q, Yang J, Liang P, Zhou J, Ma J, Ma F, Zhuan B, Zhou W.   +8 more
europepmc   +1 more source